Well Health Technologies Bets Big on AI and Clinics

Well Health Technologies ((TSE:WELL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Well Health Technologies’ latest earnings call struck an upbeat tone as management highlighted strong revenue growth, widening margins and accelerating clinic productivity, while characterizing weaker free cash flow and higher capex as temporary growing pains. Executives emphasized that operating momentum and strategic investments in AI and Canadian clinics are already translating into better KPIs, supporting confidence in their medium‑term plan.

Strong Top-Line Growth

Well Health reported Q1 revenue of $368.3 million, a 25% year-over-year jump from $294 million, underscoring solid demand across its platform. Management reaffirmed fiscal 2026 revenue guidance of $1.55 billion to $1.65 billion, implying reported growth of 11% to 18% and normalized growth of 16% to 22% when excluding Circle Medical revenue deferrals.

Margin and Profitability Expansion

Profitability expanded sharply, with adjusted EBITDA rising 56% to $43.1 million and adjusted net income climbing to $15.5 million, roughly double last year’s level. Adjusted gross profit reached $163.2 million, up 39% year over year, while adjusted gross margin improved by 440 basis points to 44.3%, signaling better operating leverage.

Canadian Clinics—High Growth and Improving Margins

Canadian clinics generated $130.3 million in Q1 revenue and are on track to materially exceed $500 million in 2026, cementing their role as a core growth engine. The segment delivered $17.0 million in adjusted EBITDA, up 28% year over year, with primary care margins rising to about 8%, aided by a four-year revenue CAGR of roughly 47% and adjusted EBITDA CAGR of about 44%.

Operational Scale and Productivity Gains

System-wide patient visits rose 17% to 1.9 million in Q1, with Canadian visits around 1.3 million, reflecting growth of roughly 31% to 33% year over year. Billable providers in Canada increased 17% to 2,204 and visits per provider climbed about 14% to 576, highlighting productivity gains that management attributes in part to AI and digital tooling.

Wellstar SaaS Momentum

Wellstar posted Q1 revenue of $21.8 million, up 27% from the prior year, demonstrating steady SaaS traction. Monthly recurring revenue reached $6.4 million, up 38% year over year, while adjusted EBITDA grew 14% to $4.9 million, or about 20% to $5.2 million when excluding spinout-related costs.

Healwell’s Rapid Scale-Up

Healwell delivered a breakout quarter, with revenue surging 316% year over year to $33.2 million as the platform gained customers across 11 countries, including the U.K.’s NHS. The unit swung to a positive adjusted EBITDA of $0.7 million from a loss of $2.3 million a year ago, pointing to improving margins alongside rapid scale.

AI-Enabled Product and Operational Wins

AI played a central role, with Well transcribing and mobilizing data from 195,000 fax images in Q1, reportedly saving physicians up to 10 hours per week through automated transcription. Healwell screened more than 59,000 patient records for disease, while Wellstar’s billing solutions surpassed a $1 billion annualized physician pay run rate, supporting a strong net promoter score of around 80.

New Strategic Platforms and Initiatives

Management launched the Well Health Intelligence Platform to unify data and AI, aiming to accelerate automation and cost optimization across the network. The company also rolled out Well Research to refocus clinical research on higher-margin Phase I trials and created CyberWell to consolidate cybersecurity tools around an AI-enabled platform, where they plan to bring in outside capital.

Balance Sheet and Liquidity Strengthened

The company ended Q1 with $134 million in cash and equivalents and expanded its senior secured credit facility to CAD 400 million, including a $100 million accordion, with maturities extended to early 2030. This effectively doubles prior credit capacity and, alongside continued share buybacks, gives Well financial flexibility to support acquisitions and ongoing investments.

Large M&A Pipeline and Capital Allocation Focus

Well detailed a sizable M&A pipeline representing more than $440 million in annual revenue across over 50 targets and 125-plus clinics, with roughly $265 million tied to Well Canada deals already at LOI or advanced stages. Management reiterated a disciplined capital allocation strategy that prioritizes Canadian clinics while exploring strategic alternatives for non-core assets, including a potential Wellstar spinout and partnerships for CyberWell.

Circle Medical’s Compliance and Deferred Revenue Effects

Circle Medical reported Q1 revenue of $36 million, up 21% year over year, aided by $12.8 million of previously deferred revenue recognized in the quarter, which complicates comparability. The company noted a decline in Circle patient visits due to compliance focus and expects only about $4.8 million of deferred revenue to be recognized in Q2, with no further deferrals thereafter, while historical billing issues remain under discussion.

Capex Surge and Free Cash Flow Pressure

Capital expenditures jumped 88% year over year in Q1, driven by investments in Healwell, clinic upgrades, Well Research, CyberWell and the new AI platform, putting pressure on near-term cash generation. Operating adjusted free cash flow attributable to shareholders fell to $1.6 million from $11.8 million a year earlier, and management acknowledged weaker near-term liquidity conversion even as they framed the spending as strategic.

U.S. Asset Weakness and Strategic Review

U.S. operations remain a mixed picture, with a strategic review underway for assets such as Wisp, Circle Medical and CRH, adding execution and timing uncertainty for investors. Wisp revenue was roughly flat at $29.1 million with a modest adjusted EBITDA loss, while CRH revenue slipped to $111.3 million from $114.3 million as staffing challenges weighed on performance.

Investment-Driven Margin Pressure and Execution Risk

Near-term margins are being compressed by investments in Well Research, CyberWell and the new AI platform, which have yet to fully flow through to earnings and free cash flow. Management expects these initiatives to drive future margin expansion but acknowledged execution risk if the cost savings and growth benefits take longer than anticipated to materialize.

Reliance on Deferred Revenue and M&A Execution

Guidance incorporates about $17.6 million of Circle Medical deferred revenue with nearly full EBITDA contribution, making results sensitive to timing and collectibility of that revenue. The company also emphasized that integrating a large pipeline of acquisitions will require scaling its transformation teams, underscoring operational risk around onboarding larger, higher-margin clinics efficiently.

Guidance and Outlook

Well reaffirmed fiscal 2026 guidance for revenue between $1.55 billion and $1.65 billion and adjusted EBITDA of $175 million to $185 million, noting that forecasts include the remaining Circle deferred revenue and only announced deals so far. Management is targeting Well Canada to reach about $800 million of run-rate revenue and more than $100 million of adjusted EBITDA within roughly 12 months and plans a second-half cost-optimization program to sustain double-digit annual growth in adjusted EBITDA and free cash flow.

The earnings call framed Well Health as a high-growth, asset-heavy platform leaning into AI and clinic expansion, even at the cost of short-term cash flow. For investors, the key takeaway is that management is doubling down on Canadian clinics, software and AI-enabled efficiency, betting that current capex and U.S. restructuring risks will be rewarded with stronger margins and more durable earnings over the next two years.